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ABSTRACT 
 
Nonspecific orofacial symptoms as risk factors for first-onset TMD and chronic TMD 
(Under the direction of Dr. Eric Bair) 
 
Previous studies found the count of 6 nonspecific orofacial symptoms was one of 
the most important predictors of first-onset TMD. We further examined the influence of 
these symptoms (jaw siftness, cramping, fatigue, pressure, soreness, and ache) on first-
onset TMD and chronic TMD among U.S. adults aged 18 to 44 years in the OPPERA 
study. We identified 259 first-onset TMD cases and 185 chronic TMD cases. Hazard 
ratios were computed to estimate the association between each nonspecific orofacial 
symptom and first-onset TMD. We calculated odds ratios to measure the association 
between each symptom and chronic TMD. A principal component analysis was used to 
determine if all six symptoms are measures of a single underlying construct or largely 
independent of one another. Multivariable cox models quantified the combined effects of 
non-specific orofacial symptoms, clinical orofacial measures, and first-onset TMD. 
Multivariable logistic models examined these same associations on chronic TMD. Each 
nonspecific orofacial symptom was significantly associated with increased incidence of 
first-onset TMD and greater odds of chronic TMD. Results from the principal component 
analysis suggest it is reasonable to summarize the six variables by simply counting the 
number of symptoms reported. In the multivariable analysis, nonspecific orofacial 
symptoms significantly predicted first-onset TMD (HR=1.33; 95% CI: 1.11-1.59) and 
chronic TMD (OR=3.06; 95% CI: 2.03-4.97). The results indicate that the count of 
nonspecific orofacial symptoms is an independent risk factor and not a surrogate variable 
for pain.  
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Introduction 
Temporomandibular disorder (TMD) is an umbrella term used to describe 
musculoskeletal disorders in the temporomandibular region. This paper focuses on 
painful forms of TMD where the defining feature is pain in the temporomandibular joint 
or the masticatory muscles.1, 2, 3 In the 2002 National Health Interview Survey, five 
percent of adults in the United States reported TMD-type pain (6% of women, 3% of 
men).4 Longitudinal studies indicate that the average incidence rate is 4% of people per 
annum.5 Most studies report that women have higher prevalence of painful TMD 
symptoms than men, with a female-to-male ratio of approximately 2:1. 6,7   
The Orofacial Pain: Prospective Evaluation and Risk Assessment (OPPERA) 
study was designed to identify potential risk factors for painful TMD. TMD etiology is 
multifactorial, with biological, psychological, and social models of causation currently 
favored. Although previous studies have identified risk factors for TMD, we could not 
clearly indicate whether risk factors predated TMD onset or were a consequence of TMD 
because of the cross-sectional study design. OPPERA overcomes this limitation by 
conducting a prospective cohort study of initially TMD-free individuals. By using this 
design, we can establish a temporal sequence that links risk factors measured prior to 
TMD onset to case development.3 
Ohrbach and Bair previously explored clinical characteristics associated with 
TMD development.8, 9 One characteristic evaluated was nonspecific orofacial symptoms, 
which are orofacial symptoms that are not primarily painful. These six symptoms were: 
jaw stiffness, cramping, fatigue, pressure, soreness, and ache. Bair found that count of 6 
nonspecific orofacial symptoms was one of the most important predictors of first-onset 
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TMD. One hypothesis to explain this association is that nonspecific orofacial symptoms 
are merely a precursor to painful TMD, rather than an independent risk factor. If 
nonspecific orofacial symptoms are a surrogate variable for known risk factors, then the 
theoretical and practical relevance will be diminished.  
The aim of this paper is to further investigate the influence of nonspecific 
orofacial symptoms on TMD onset and chronic TMD. Specifically, we will use principal 
components analysis to better understand the nature of this count of nonspecific orofacial 
symptoms. We also used multivariable regression to determine if the associations 
between this count and TMD can be explained by surrogate measures of clinical TMD or 
major risk factors for TMD (e.g., jaw pain or function limitation) or if it represents an 
independent risk factor for TMD. 
 
Methods 
Study Design 
This paper reports findings from the OPERRA prospective cohort study of first-
onset TMD and the baseline case-control study of chronic TMD. Study methods are 
explained briefly below and in more depth in previous papers.10 The target population 
was community-based volunteers aged 18 to 44 years. To provide a demographically 
diverse sample, there were 4 recruitment sites: Baltimore, MD; Buffalo, NY; Chapel Hill, 
NC; and Gainesville, FL. Most participants heard of the study through advertisements, 
word of mouth, or email. The OPPERA project was reviewed and approved by 
institutional review boards at the 4 study sites and at the data-coordinating center, 
Battelle Memorial Institute. Study participants provided signed consent to participate. At 
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baseline, all participants completed a questionnaire, clinical examination, measurement of 
pain perception and autonomic function, and collection of a blood sample.  
Trained examiners classified TMD based on the Research Diagnostic Criteria for 
Temporomandibular Disorders. Briefly, people were classified as chronic TMD cases if 
they met the following criteria: 1) frequently reported pain in the cheeks, jaw muscles, 
temples, or jaw joints during the past 6 months; 2) pain in the orofacial region for at least 
5 days in the past month; and 3) evoked pain in at least 3 masticatory muscles or at least 
1 tempormandibular joint in response to examiner’s palpation of orofacial muscle 
palpation or jaw maneuver. The 6-month time criterion is consistent with the 1994 IASP 
recommended threshold for research in chronic pain.13 First-onset TMD cases satisfied 
the following criteria: 1) pain within anatomic locations for more than 5 of the past 30 
days and 2) examiner findings of pain in muscles, joints, or both from jaw maneuver and 
digital palpation of masticatory structures.10 Participants classified as controls met the 
following criteria: 1) no previous diagnosis of TMD; 2) infrequent facial pain during the 
past 5 months and infrequent headache in the past 3 months; 3) no more than 4 days of 
facial pain in the past month; and 4) no use of night guard of occlusal splint.12 Non-
specific orofacial symptoms in the past month were assessed with a 6-item check list.  
 
Study Design  
The unmatched case-control study enrolled 3,247 controls and 185 chronic TMD 
cases between 2006 and 2008. Controls were selected among the participants in the 
prospective cohort study using a stratified random sample. Among the 3,247 controls, 
2,731 completed at least one follow up questionnaire and were included in the 
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prospective cohort study. Follow-up questionnaires were conducted every 3 months 
through mid-2012 to screen for TMD symptoms. Questions inquired about “headaches or 
pain in your face, jaw, temples in front of the ear, or in the ear”, which is defined as 
orofacial pain. The self-reported questionnaires were completed at home prior to a 
follow-up clinical examination.  Examiners re-evaluated symptomatic study participants, 
and 259 people were classified with first-onset TMD. Examiners did not refer to 
questionnaire responses during the diagnosis of TMD.  More detailed information about 
the follow-up questionnaires and clinical assessments can be found in other papers.14 
 
Statistical Analysis 
First, each non-specific orofacial symptom was individually assessed. The 
univariate association between each symptom and first-onset TMD was examined using 
Cox proportional hazards regressions. Hazard ratios (HRs), 95% confidence intervals 
(95% CIs), and p-values were computed. Although the hazard ratio is a theoretical 
construct, it provides a good approximate of the average incidence rate-ratio in a cohort 
study. The Cox proportional hazards models have convenient statistical advantages over 
other methods that model the incidence rate directly. HRs were adjusted for study site 
and the following demographics: age, gender (male, female) and race/ethnicity (White, 
African-American/Black, Hispanic, Asian, and Other). To evaluate the association 
between each non-specific orofacial symptom and chronic TMD, logistic regression was 
used. ORs, 95% CIs, and p-values were calculated. ORs were adjusted for study site and 
demographic variables. 
6 
Principal component analysis is a technique used to model the variation between a 
set of variables. This procedure was used to determine if all six symptoms are measures 
of a single underlying construct or if the variables are largely independent of one another. 
The correlation between each of the six symptoms was also computed. 
 Multivariable models were used to further examine the effects of nonspecific 
orofacial symptoms and determine whether non-specific orofacial symptoms act as a 
substitute variable for pain, jaw function limitation, or somatic awareness.A multivariable 
Cox regression model was used to estimate the combined effects of non-specific orofacial 
symptom count, various clinical pain measures, study site, and demographic variables on 
TMD incidence. The following clinical pain variables were included in the multivariable 
model: the Facial Pain Intensity Score from the Graded Chronic Pain Scale, the global 
score for the Pennebaker Inventory Limbic Languidness, and number of palpation tender 
points in the following regions: right temporalis, left temporalis, right masseter, left 
masseter, right mandibular, left mandibular, right lateral pterygoid, left lateral pterygoid, 
right temporomandibular (TM) joint, and left TM joint. Pain in response to palpation 
tender points in these regions is part of TMD case-classification. These clinical pain 
measures were selected because they may be a surrogate variable for the number of non-
specific orofacial symptoms. Three separate models were tested: one crude model, one 
model adding demographics variables, and one model adding demographic and clinical 
pain variables. All models were adjusted for study site. HRs and 95% CIs were 
calculated. A multivariable logistic regression model was also conducted to examine the 
association between these same variables and chronic TMD. ORs and 95% CIs were 
computed from the same three types of models. 
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Results 
Brief demographic information is reported in Table 1. More detailed descriptive 
statistics have been reported in previous OPPERA papers.10 In the prospective cohort 
study, 2,731 initially TMD-free participants were followed for a total of 7,378 person-
years (median=2.8 years/person). During this time, 259 people developed first-onset 
TMD. The baseline case-control study consisted of 185 chronic TMD cases and 3247 
controls. Participants were more likely to be 18-24 years old (51.7%), female (58.6%), 
and white (51.6%).  
 
Assessment of each non-specific orofacial symptom 
Hazard ratios and 95% confidence intervals for the associations between each 
non-specific orofacial symptom and TMD incidence are presented in Table 2. For each 
non-specific orofacial symptom, presence of the symptom predicted TMD incidence. The 
strongest predictor of TMD incidence was cramping in the past 6 months (HR=3.09; 95% 
CI: 1.77-5.40). Cramping was reported in 4% of TMD cases. The weakest predictor is 
fatigue (HR=1.43; 95% CI: 0.90-2.25). 
ORs and 95% CIs estimating the association between nonspecific orofacial 
symptoms and chronic TMD are displayed in Table 3. Each non-specific orofacial 
symptom is significantly associated with chronic TMD. Ache in the past 6 months is the 
strongest association (OR=167.36; 95% CI: 88.83-322.57). 95% of TMD cases reported 
jaw ache. 
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Relationship between the non-specific orofacial symptoms 
Table 4 illustrates the correlation between each non-specific orofacial symptom. 
The 6 symptoms are moderately correlated, with correlations ranging from 0.40 to 0.63. 
Ache and soreness are the most correlated (r=0.63). 
The scree plot for the principal component analysis is shown in Figure 1. The first 
component explains the majority of the variance (variances greater than 3.0). The five 
remaining components explain a smaller proportion of the variance in the data. All the 
loadings are approximately equal, indicating that it is reasonable to summarize the six 
variables by simply counting the number of symptoms reported. 
 
Multivariable Models 
The HRs and 95% CIs for the multivariable association between nonspecific 
orofacial symptoms and first-onset TMD are shown in Table 6. The count of nonspecific 
orofacial symptoms significantly predicts incidence of first-onset TMD in all 3 models. 
After adding clinical pain variables in model 3, the number of nonspecific orofacial 
symptoms remains significantly associated with increased incidence of first-onset TMD 
(HR=1.33; 95% CI: 1.11-1.59). This suggests that count of non-specific orofacial 
symptoms is not a substitute for any of the clinical pain variables, but rather an 
independent risk factor that is associated with increased incidence of first-onset TMD. 
Table 7 displays the ORs and 95% CIs for the multivariable association between 
nonspecific orofacial symptoms and chronic TMD. In the first 2 models, the crude model 
and the model that includes demographic variables, the count of nonspecific orofacial 
symptoms is significantly associated with chronic TMD. When the clinical pain variables 
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were added in model 3, the symptom count was significantly associated with greater odds 
of chronic TMD (OR=3.06; 95% CI: 2.03-4.97). ! !
10 
Table 1. Descriptive Characteristics of OPPERA Study Participants 
    
Baseline Case-Control 
Study Prospective Cohort Study 
Characteristics; 
N (%) Total 
Cases 
(Chronic 
TMD) Controls 
Cases (First On-
Set TMD) Controls 
All People 3432 185 3247 259 2472 
Age (years) 
        18-24 1773 (51.7) 72 (38.9) 1701 (52.4) 110 (42.5) 1307 (52.9) 
   25-34 919 (26.8) 60 (32.4) 859 (26.5) 78 (30.1) 656 (26.5) 
   35-44 740 (21.6) 53 (28.7) 687 (21.2) 71 (27.4) 509 (20.6) 
Gender 
        Male 1420 (41.4) 30 (16.2) 1390 (42.8) 92 (35.5) 1014 (41.0) 
   Female 2012 (58.6) 155 (83.8) 1857 (57.2) 167 (64.5) 1458 (59.0) 
Race 
        White 1771 (51.6) 128 (74.6) 1633 (50.3) 138 (53.3) 1304 (52.8) 
   Black 1030 (30.0) 25 (13.5) 1005 (31.0) 86 (33.2) 680 (27.5) 
   Asian 305 (8.9) 6 (3.2) 299 (9.2) 9 (3.5) 247 (10.0) 
   Hispanic 223 (6.5) 12 (6.5) 211 (6.5) 19 (7.3) 159 (6.4) 
   Other 103 (3.0) 4 (2.2) 99 (3.1) 7 (2.7) 82 (3.3) 
Study Site 
        Baltimore, MD 871 (25.4) 56 (30.3) 815 (25.1) 30 (11.6) 675 (27.3) 
   Buffalo, NY 820 (25.9) 23 (12.4) 797 (24.6) 71 (27.4) 622 (25.2) 
   Chapel Hill, NC 937 (27.3) 60 (32.4) 877 (27.0) 101 (39) 660 (26.7) 
   Gainesville, FL 804 (23.4) 46 (24.9) 758 (23.3) 57 (22.0) 515 (20.8) 
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Table 2. Univariate Associations between Non-Specific Orofacial Symptoms and 
Incidence Rate of First-Onset TMD 
Symptom 
TMD-free; 
N (%) 
First-Onset 
TMD cases; 
N(%) HR (95% CI)* 
Adjusted HR 
(95% CI)** P Value 
Stiffness 
        Yes 145 (6) 33 (13) 1.13 (0.74, 1.72) 1.80 (1.20, 2.71) 0.005 
   No 2323 (94) 225 (87) 1.00 1.00 . 
 
      Cramping 
        Yes 54 (2) 11 (4) 2.36 (1.23, 4.54) 3.09 (1.77, 5.40) <0.001 
   No 2414 (98) 247 (96) 1.00 1.00. 
 
      Fatigue 
        Yes 125 (5) 29 (11) 1.18 (0.78, 1.78) 1.43 (0.90, 2.25) 0.128 
   No 2342 (95) 229 (89) 1.00 1.00. 
 
      Pressure 
        Yes 117 (5) 31 (12) 1.75 (1.20, 2.56) 1.80 (1.20, 2.71) 0.004 
   No 2350 (95) 227 (88) 1.00 1.00. 
 
      Soreness 
   
 
    Yes 139 (6) 38 (15) 2.16 (1.51, 3.08) 2.20 (1.58, 3.06) <0.001 
   No 2330 (94) 220 (85) 1.00 1.00. 
 
      Ache 
        Yes 200 (8) 44 (17) 2.01 (1.46, 2.76) 2.12 (1.53, 2.93) <0.001 
   No 2267 (92) 212 (83) 1.00 1.00.   
*Adjusted for study site 
**Adjusted for study site, age, gender, and race 
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Table 3. Univariate Associations Between Nonspecific Orofacial Symptoms 
and Chronic TMD   
Symptom 
TMD-
free; 
N(%) 
TMD 
cases; 
N(%) OR (95% CI)* 
Adjusted OR  
(95% CI)** P Value 
Stiffness 
        Yes 215 (7) 169 (92) 163.66 (94.57, 283.22) 156.73 (90.00, 272.94) <.001 
   No 3025 (93) 15 (8) 1.00 . 1.00 . 
 
      Cramping 
        Yes 83 (3) 79 (43) 30.96 (21.29, 45.03) 34.49 (22.95, 51.85) <.001 
   No 3156 (97) 103 (57) 1.00. 1.00. 
 
      Fatigue 
        Yes 183 (6) 130 (71) 42.66 (29.84, 60.98) 42.08 (29.01, 61.03) <.001 
   No 3054 (94) 52 (29) 1.00 . 1.00. 
 
      Pressure 
        Yes 177 (5) 138 (75) 55.63 (38.24, 80.94) 48.51 (33.10, 71.09) <.001 
   No 3060 (95) 46 (25) 1.00. 1.00. 
 
      Soreness 
        Yes 218 (7) 164 (90) 140.63 (84.04, 235.33) 135.32 (80.23, 228.24) <.001 
   No 3022 (93) 18 (10) 1.00. 1.00. 
 
      Ache 
        Yes 300 (9) 173 (95) 183.34 (95.43, 352.25) 167.36 (86.83, 322.57) <.001 
   No 2934 (91) 10 (5) 1.00. 1.00.   
*Adjusted for study site 
**Adjusted for study site, age, gender, and race 
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Table 4. Correlation Matrix for Nonspecific Orofacial Symptoms 
 Stiffness Cramping Fatigue Pressure Soreness Ache 
Stiffness 1.00 0.47 0.53 0.55 0.57 0.53 
Cramping 0.47 1.00 0.41 0.43 0.42 0.40 
Fatigue 0.53 0.41 1.00 0.47 0.47 0.44 
Pressure 0.55 0.43 0.47 1.00 0.56 0.56 
Soreness 0.57 0.42 0.47 0.56 1.00 0.63 
Ache 0.53 0.40 0.44 0.56 0.63 1.00 
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Figure 1. Scree Plot of the Nonspecific Orofacial Symptoms PCA Results 
 
Table 5. Matrix of Loadings for the PCA Results of the First Component 
 Stiffness Cramping Fatigue Pressure Soreness Ache 
PC1 -0.43 -0.36 -0.39 -0.42 -0.43 -0.42 
 
 
 
  
Scree Plot of the Nonspecific Orofacial Symptoms PCA Results
V
ar
ia
nc
es
0.
0
0.
5
1.
0
1.
5
2.
0
2.
5
3.
0
15 
Table 6. Multivariable-Adjusted Associations between Nonspecific Orofacial Symptoms and 
First-Onset TMD  
 
 
 
 
Model 1* 
 
Model 2* 
 Add: Demographics 
 
Model 3*  
Add: Pain Measures 
Variable Coding 
HR  
(95% CI) P Value   
HR  
(95% CI) P Value   
HR  
(95% CI) P Value 
Number of 
nonspecific 
orofacial symptoms 
z-score 1.32  (1.21, 1.45) <0.001   
1.31  
(1.20, 1.43) <0.001   
1.23  
(1.09, 1.39) 0.001 
*All models adjusted for study site 
       
Table 7. Multivariable-Adjusted Associations between Nonspecific Orofacial Symptoms and 
Chronic TMD 
 
  
Model 1* 
 
Model 2*  
Add: Demographics 
 
Model 3*  
Add: Pain Measures 
Variable Coding 
OR  
(95% CI) 
P 
Value   
OR  
(95% CI) P Value   
OR  
(95% CI) P Value 
Number of 
nonspecific 
orofacial symptoms 
z-score 4.51  (3.80, 5.47) <0.001   
4.93 
(4.03, 6.23) <0.001   
3.06 
(2.03, 4.97) <0.001 
*All models adjusted for study site 
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Discussion 
Bair previously found that count of 6 nonspecific orofacial symptoms was one of 
the most important predictor of first-onset TMD.9 Here we show that during the median 
2.8 follow-up years of the OPPERA prospective cohort study, each of the 6 nonspecific 
orofacial symptoms individually predicted incidence of TMD. In the baseline case-
control study, each individual nonspecific orofacial symptom is also significantly 
associated with greater odds of chronic TMD. Though the correlation matrix shows that 
nonspecific orofacial symptoms are interrelated, the count of symptoms represents an 
individual construct. The principal component analysis further supports this conclusion, 
since the large majority of the variance was captured by the first component. Since each 
of the symptoms produced similar loadings, that indicates that a simple count of the 
symptoms provides an adequate measure of this construct. 
In the multivariable analysis, the count of nonspecific orofacial symptoms is a 
significant predictor of first-onset TMD even after the addition of demographic variables 
and clinical pain measures. The significance of the symptom count in the fully adjusted 
model corroborates the hypothesis that count of nonspecific orofacial symptoms predicts 
chronic TMD independently of other risk factors. One hypothesis to explain the strength 
of the association between symptom count and TMD was that these symptoms 
represented measures of pain or preclinical TMD symptoms, so it would not be surprising 
that those with nonspecific orofacial symptoms converted to acute TMD. However, we 
now see that this is not the case, as the symptom count remains significant after including 
the pain variables. Indeed, the effect size of the symptom count is hardly modified when 
clinical pain measures are added. This suggests that the number of nonspecific orofacial 
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symptoms is not simply a surrogate variable for pain. These 6 symptoms were asked in 
the questionnaire to capture experiences that were seemingly adverse, but did not fit the 
definition of “pain” used for TMD case classification. Ohrbach previously suggested that 
the neurobiology underlying the semantics of the nonspecific orofacial symptoms is 
likely different from pain. These findings support Ohrbach’s hypothesis. 
In summary, the count of nonspecific orofacial symptoms represents an 
independent construct that predicts both first-onset and chronic TMD independently of 
other risk factors. The number of symptoms is not a substitute variable for pain, but its 
own its own risk factor. 
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